Latest News and Press Releases

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod· The clinical Phase 3 study...

LUND, Sweden, April 26, 2016 (GLOBE NEWSWIRE) -- The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 26, 2016,...

Styrelsen för Active Biotech AB (publ) har utfärdat kallelse till årsstämma, vilken kommer äga rum torsdagen den 26 maj 2016 klockan 17.00 på Elite Hotel Ideon, Scheelevägen 27 i Lund. Kallelsen,...

The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 26, 2016, at 5 pm at Elite Hotel Ideon, Scheelevägen 27...

LUND, Sweden, April 26, 2016 (GLOBE NEWSWIRE) -- The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 26, 2016,...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Styrelsen för Active Biotech AB (publ) har...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The Board of Directors of Active...

Lund, March 23, 2016 - Active Biotech (Nasdaq Stockholm: ACTI) today announces that a patent application for the treatment of multiple myeloma with the company's compound tasquinimod, together with...

Lund den 23 mars 2016 - Active Biotech (Nasdaq Stockholm: ACTI) meddelar idag att en patentansökan för behandling av multipelt myelom med bolagets substans tasquinimod, tillsammans med en så kallad...

LUND, Sweden, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Laquinimod In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment...